Taysha Gene Therapies
Advances TSHA-102, an AAV9 gene therapy in pivotal testing for Rett syndrome.
$5.87
After-hours close+0.10 (+1.73%)
At close$5.77(−3.19%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 83.04%265.63M sharesInsiders 2.18%6.96M sharesOther 14.78%47.27M shares
Shares outstanding 319.86M · Float 265.14M · 82.9% free float
Institutions13F, as of Mar 31, 2026
196 holders · 265.63M shares · 34 new positions · 103 increased · 49 reduced · 40 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 23.56M | 7.36% | 0 | May 15, 2026 |
| Goldman Sachs Group Inc | 22.37M | 6.99% | +8.68M | May 15, 2026 |
| Avoro Capital Advisors LLC | 21.70M | 6.78% | 0 | May 15, 2026 |
| BlackRock, Inc. | 18.37M | 5.74% | −277.5K | May 13, 2026 |
| Vestal Point Capital, LP | 18.00M | 5.63% | +4.25M | May 15, 2026 |
| Morgan Stanley | 17.97M | 5.62% | −113.1K | May 15, 2026 |
| FMR LLC | 14.32M | 4.48% | +792.9K | May 15, 2026 |
| RTW Investments, LP | 13.68M | 4.28% | −2.72M | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Avoro Capital Advisors LLCincl. Behzad Aghazadeh | 9.99% | 23.09M | 13G | Nov 14, 2024 ↗ |
| RA Capital Management, L.P. | 9.90% | 27.66M | 13G | Nov 14, 2025 ↗ |
| Paul B Manningincl. The Paul B. Manning Revocable Trust dated May 10, 2000, The PBM 2023 Grantor Retained Annuity Trust +3 more | 9.80% | 25.60M | 13D | Jun 3, 2025 ↗ |
| RTW Investments, LP | 7.00% | 20.69M | 13G | May 15, 2026 ↗ |
| Morgan Stanley | 6.70% | 16.86M | 13G | Aug 6, 2025 ↗ |
| BlackRock, Inc. | 6.50% | 17.85M | 13G | Jan 21, 2026 ↗ |
| Vestal Point Capital, LP | 6.30% | 18.00M | 13G | May 15, 2026 ↗ |
| The Goldman Sachs Group, Inc. | 5.10% | 12.75M | 13G | Jul 3, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Sean P. Nolan | director, officer: Chief Executive Officer | 2.91M | 0.91% | Jan 27, 2026 |
| Manning Paul B | 10 percent owner | 2.84M | 0.89% | Jun 3, 2025 |
| Kamran Alam | officer: CHIEF FINANCIAL OFFICER | 1.44M | 0.45% | Feb 6, 2026 |
| John A. III Stalfort | director | 1.18M | 0.37% | Jun 2, 2026 |
| Sukumar Nagendran | director, officer: President and Head of R&D | 936.4K | 0.29% | Jul 10, 2026 |
| Phillip B. Donenberg | director | 241.3K | 0.08% | Jun 2, 2026 |
| Alison S. Long | director | 127.2K | 0.04% | Jun 2, 2026 |
| Laura Sepp-Lorenzino | director | 127.2K | 0.04% | Jun 2, 2026 |
2 ten-percent owners hold 11.71M shares by Form 4, outside the officers-and-directors figure above · 2 people have not refiled in the last 18 months (7.81M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 10, 2026 | Sukumar Nagendrandirector, officer: President and Head of R&D | Sale | 200,000 | $6.24 | 936,410 |
| Apr 10, 2026 | Sukumar Nagendrandirector, officer: President and Head of R&D | Sale | 200,000 | $4.46 | 1,136,410 |
| Feb 4, 2026 | Kamran Alamofficer: CHIEF FINANCIAL OFFICER | Sale | 1,655 | $4.52 | 1,442,131 |
| Jan 26, 2026 | Kamran Alamofficer: CHIEF FINANCIAL OFFICER | Sale | 23,849 | $4.61 | 1,443,786 |
| Jan 23, 2026 | Kamran Alamofficer: CHIEF FINANCIAL OFFICER | Sale | 78,968 | $4.75 | 1,467,635 |
| Jan 26, 2026 | Sean P. Nolandirector, officer: Chief Executive Officer | Sale | 41,312 | $4.61 | 2,908,257 |
| Jan 23, 2026 | Sean P. Nolandirector, officer: Chief Executive Officer | Sale | 136,789 | $4.75 | 2,949,569 |
| Jan 26, 2026 | Sukumar Nagendrandirector, officer: President and Head of R&D | Sale | 26,918 | $4.61 | 1,317,389 |
| Jan 23, 2026 | Sukumar Nagendrandirector, officer: President and Head of R&D | Sale | 89,132 | $4.75 | 1,344,307 |
| Jan 12, 2026 | Sukumar Nagendrandirector, officer: President and Head of R&D | Sale | 200,000 | $4.71 | 1,006,439 |
CongressHouse and Senate disclosures
Not reported.